Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials

Christopher Em Griffiths; Kristian Reich; Mark Lebwohl; Peter van de Kerkhof; C. Paul; Alan Menter; Gregory S. Cameron; J. Erickson; Lu Zhang; Roberta J. Secrest; Susan Ball; Daniel Braun; Olawale Osuntokun; Michael Heffernan; Brian J. Nickoloff; Kim Papp

doi:10.1016/s0140-6736(15)60125-8

Related publications

Article2017

Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3)

Andrew Blauvelt, Kim Papp, Christopher Em Griffiths, L. Puig, Jamie Weisman, Yves Dutronc, Lisa Farmer Kerr, Dapo Ilo, Lotus Mallbris, Matthias Augustin

Article2020

Efficacy and Safety of Ixekizumab Through 5 Years in Moderate-to-Severe Psoriasis: Long-Term Results from the UNCOVER-1 and UNCOVER-2 Phase-3 Randomized Controlled Trials

Craig L. Leonardi, Kristian Reich, Peter Foley, Hideshi Torii, Sascha Gerdes, Lyn Guenther, Melinda Gooderham, Laura K. Ferris, Christopher Em Griffiths, Hany Elmaraghy, Heidi M. Crane, Himanshu J. Patel, Russel Burge, Gaia Gallo, David Shrom, Ann N. Leung, Chen‐Yen Lin, Kim Papp

Article2010

Comparison of Ustekinumab and Etanercept for Moderate-to-Severe Psoriasis

Christopher Em Griffiths, Bruce Strober, Peter van de Kerkhof, Vincent Ho, Roseanne Fidelus-Gort, Newman Yeilding, Cynthia Guzzo, Yichuan Xia, B. Zhou, Shu Li, Lisa T. Dooley, Neil Goldstein, Alan Menter

Article2023

Efficacy of ixekizumab in patients with moderate-to-severe plaque psoriasis and prediabetes or type 2 diabetes

Alexander Egeberg, Joseph F. Merola, Knut Schäkel, L. Puig, Patrick Mahar, Isabella Yali Wang, Imre Pávó, Christopher Schuster, Christopher Em Griffiths

Corrigendum2023

Corrigendum: Efficacy of ixekizumab in patients with moderate-to-severe plaque psoriasis and prediabetes or type 2 diabetes